A recent assessment by the Institute for Clinical and Economic Review (ICER) of a new class of migraine treatments – calcitonin gene-related peptide (CGRP) inhibitors – fails to incorporate improvements to patients’ productivity in its price recommendations despite evidence that the impact of migraines on patient productivity is significant. ICER’s biased assessment also goes against best practices recommended by experts in the field of cost-effectiveness analysis and highlights how their approach skews results to put payer needs over patients. Download the case study to learn more.